Cary Twyman

1.7k total citations · 1 hit paper
17 papers, 1.0k citations indexed

About

Cary Twyman is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Cary Twyman has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Cary Twyman's work include Multiple Sclerosis Research Studies (11 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Polyomavirus and related diseases (4 papers). Cary Twyman is often cited by papers focused on Multiple Sclerosis Research Studies (11 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Polyomavirus and related diseases (4 papers). Cary Twyman collaborates with scholars based in United States, United Kingdom and Czechia. Cary Twyman's co-authors include David Margolin, Eva Havrdová, Pedro Oyuela, Douglas L. Arnold, Christian Confavreux, Alasdair Coles, Krzysztof Selmaj, Howard L. Weiner, Michael Panzara and Edward Fox and has published in prestigious journals such as The Lancet, Neurology and The Journal of Organic Chemistry.

In The Last Decade

Cary Twyman

17 papers receiving 990 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

2012 884 citations Alasdair Coles, Cary Twyman et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cary Twyman United States	7	823	324	301	284	238	17	1.0k
Tamara Miller United States	6	799 1.0×	319 1.0×	288 1.0×	244 0.9×	247 1.0×	23	958
M. Stojanovic Serbia	8	815 1.0×	361 1.1×	271 0.9×	241 0.8×	249 1.0×	18	1.0k
Bella Ertik United States	5	756 0.9×	286 0.9×	272 0.9×	248 0.9×	236 1.0×	7	930
Pedro Oyuela United States	7	938 1.1×	362 1.1×	368 1.2×	326 1.1×	286 1.2×	16	1.2k
Timon Bogumil Germany	12	561 0.7×	216 0.7×	186 0.6×	181 0.6×	230 1.0×	21	1.2k
Lorenzo De Paoli Italy	15	650 0.8×	104 0.3×	311 1.0×	338 1.2×	9 0.0×	47	1.2k
Lingyan Ping China	15	383 0.5×	87 0.3×	426 1.4×	219 0.8×	16 0.1×	68	802
Jennifer L. Crombie United States	15	406 0.5×	119 0.4×	421 1.4×	141 0.5×	8 0.0×	63	822
Alan R. Yuen United States	14	595 0.7×	161 0.5×	875 2.9×	566 2.0×	12 0.1×	22	1.5k
Gudrun Zulehner Austria	15	220 0.3×	180 0.6×	272 0.9×	85 0.3×	35 0.1×	46	946

Countries citing papers authored by Cary Twyman

Since Specialization

Citations

This map shows the geographic impact of Cary Twyman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cary Twyman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cary Twyman more than expected).

Fields of papers citing papers by Cary Twyman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cary Twyman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cary Twyman. The network helps show where Cary Twyman may publish in the future.

Co-authorship network of co-authors of Cary Twyman

This figure shows the co-authorship network connecting the top 25 collaborators of Cary Twyman. A scholar is included among the top collaborators of Cary Twyman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cary Twyman. Cary Twyman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Lovett‐Racke, Amy E., Matthew Gormley, Yue Liu, et al.. (2019). B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. Journal of Neuroimmunology. 332. 187–197. 39 indexed citations

Inglese, Matilde, Maria Petracca, Sirio Cocozza, et al.. (2018). Final MRI Results At 6 Months From A Phase 2 Multicenter Study Of Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Patients With Relapsing Forms Of Multiple Sclerosis (RMS), Demonstrates Complete Elimination Of Gd-Enhancing Lesions (P3.409). Neurology. 90(15_supplement). 1 indexed citations

Brinar, Vesna, Gavin Giovannoni, Eva Havrdová, et al.. (2015). A Phase 3b/4 Long-Term Study of Alemtuzumab in Patients With Relapsing-Remitting Multiple Sclerosis: TOPAZ Study Design (P7.219). Neurology. 84(14_supplement). 3 indexed citations

Twyman, Cary, Pedro Oyuela, Jeffrey Palmer, David Margolin, & Colin Dayan. (2014). Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (P2.199). Neurology. 82(10_supplement). 11 indexed citations

Hartung, Hans, Timothy Vollmer, Douglas L. Arnold, et al.. (2013). Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093). Neurology. 80(7_supplement). 2 indexed citations

Sørensen, Per Soelberg, Douglas L. Arnold, Jeffrey A. Cohen, et al.. (2013). Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101). Neurology. 80(7_supplement). 4 indexed citations

Giovannoni, Gavin, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120). Neurology. 80(7_supplement). 1 indexed citations

Wray, Sibyl, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172). Neurology. 80(7_supplement). 1 indexed citations

LaGanke, Christopher, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174). Neurology. 80(7_supplement). 3 indexed citations

10.

Fox, Edward, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001). Neurology. 80(7_supplement). 11 indexed citations

11.

Twyman, Cary, Xavier Montalbán, Douglas L. Arnold, et al.. (2013). Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098). Neurology. 80(7_supplement). 1 indexed citations

12.

Freedman, Mark S., Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111). Neurology. 80(7_supplement). 2 indexed citations

13.

Margolin, David, Gary D. Smith, Douglas L. Arnold, et al.. (2013). Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy. Journal of the Neurological Sciences. 333. e375–e376. 7 indexed citations

14.

Cohen, Jeffrey, Cary Twyman, Douglas L. Arnold, et al.. (2012). Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004). Neurology. 78(Meeting Abstracts 1). S01.004–S01.004. 5 indexed citations

15.

Coles, Alasdair, Cary Twyman, Douglas L. Arnold, et al.. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 380(9856). 1829–1839. 884 indexed citations breakdown →

16.

Twyman, Cary & Joseph R. Berger. (2010). A giant MS plaque mimicking PML during natalizumab treatment. Journal of the Neurological Sciences. 291(1-2). 110–113. 10 indexed citations

17.

Bordwell, F. G., Jin Cheng, A. V. Satish, & Cary Twyman. (1992). Acidities and homolytic bond dissociation energies (BDEs) of benzyl-type carbon-hydrogen bonds in sterically congested substrates. The Journal of Organic Chemistry. 57(24). 6542–6546. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact